• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

PhereSys(TM) Therapeutics Appoints John Ball, MD, As Its Midwest Regional Medical Director

Posted on: Monday, 17 October 2005, 09:00 CDT

PhereSys Therapeutics Corporation ("PhereSys") announced today that John Ball, MD, has joined PhereSys Therapeutics as its Midwest Regional Medical Director. Dr. Ball graduated from the George Washington University School of Medicine and was the Clinical Assistant Professor of Medicine at the University of Illinois at Chicago before assuming his current positions as Medical Director at Logan Square Dialysis and Chief, Section of Nephrology, at the Illinois Masonic Medical Center in Chicago. He has over 25 years' experience in the fields of nephrology and therapeutic apheresis, and has published numerous scientific articles. Dr. Ball is board certified by the National Board of Medical Examiners, the American Board of Internal Medicine and the American Board of Nephrology.

Richard Davis, Chairman and CEO of PhereSys Therapeutics, stated: "We are fortunate that Dr. Ball has accepted the position as our Midwest Regional Medical Director. Dr. Ball's extensive academic and practical experience will be instrumental in our development of innovative methods of delivering therapeutic apheresis services to hospitals and physician practices. Such methods now include the establishment of PhereSys Centers of America(TM) specialty clinics -- where patients can obtain convenient, cost-effective apheresis treatments, and where participating physicians' practices can expand their therapeutic armamentarium while adding a new source of revenue."

About PhereSys Therapeutics Corporation

PhereSys Therapeutics (www.pheresys.com) is a privately held company founded to become the premier therapeutic apheresis and cellular therapies provider in the United States. Therapeutic apheresis, or "blood filtering," is a medical procedure where whole blood is separated into its components in order to remove disease-causing substances for therapeutic purposes. The Company currently provides its services to hospitals and physicians' offices in California and New York. PhereSys is scaling up an aggressive nationwide expansion of its business model with new initiatives now underway in Minnesota, Illinois and Texas. At least 10 other states are scheduled for operations in the coming year. PhereSys' strategy involves establishing a nationwide network of fully licensed and certified apheresis and cellular therapy alternate-site clinics which will serve to anchor its mobile business as well as consolidate its strategic relationships with hospitals, TA providers and blood banks. In addition, select facilities will be designated as "PhereSys Centers of America" to assist promising TA technology companies and pharmaceutical and biotech companies in pursuit of clinical trials and to further the development and commercialization of their TA, stem cell and other advanced cellular therapies.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may vary. We do not undertake to update any forward-looking statements.

Source: Business Wire

More News in this Category